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Altered placental function as a consequence of aberrant imprinted gene expression may be one mechanism
mediating the association between low birth weight and increased cardiometabolic disease risk. Imprinted gene
expression is regulated by epigenetic mechanisms, particularly DNA methylation (5mC) at differentially methylated
regions (DMRs). While 5-hydroxymethylcytosine (5hmC) is also present at DMRs, many techniques do not distinguish
between 5mC and 5hmC. Using human placental samples, we show that the expression of the imprinted gene CDKN1C
associates with birth weight. Using speciﬁc techniques to map 5mC and 5hmC at DMRs controlling the expression of
CDKN1C and the imprinted gene IGF2, we show that 5mC enrichment at KvDMR and DMR0, and 5hmC enrichment
within the H19 gene body, associate positively with birth weight. Importantly, the presence of 5hmC at imprinted DMRs
may complicate the interpretation of DNA methylation studies in placenta; future studies should consider using
techniques that distinguish between, and permit quantiﬁcation of, both modiﬁcations.
Introduction
An abundance of evidence from human and animal studies
has shown that low weight at birth is associated with an increased
risk of cardiometabolic and neuroendocrine disease in later life.1
The factors that determine size at birth are complex but include
differences in placental size and function.2 Imprinted genes,
which are preferentially expressed from one parental allele only,
are of particular importance in determining normal placental
growth and transfer capacity, notably transport of the nutrients
essential for normal fetal growth.3 Evidence from mouse models
and humans suggests that genes that are paternally expressed tend
to increase fetal growth, whereas maternally expressed genes
restrict fetal growth. The expression of imprinted genes is largely
regulated by epigenetic mechanisms, particularly DNA methyla-
tion (5-methylcytosine; 5mC) at differentially methylated regions
(DMRs). Aberrant imprinting leads to abnormalities of both pla-
cental and fetal growth in animal models.4-7 In addition, altered
placental expression of imprinted genes has been reported in
association with human fetal growth restriction.8-10
The imprinted insulin-like growth factor 2 (IGF2) gene has a
major role in the matching of placental nutrient supply to fetal
demand,4 and altered IGF2 expression has been reported in
association with fetal growth restriction in humans.9,10 IGF2,
and the neighboring H19 gene, are situated in an imprinted
gene cluster on human chromosome 11p15. Expression of the
paternally expressed IGF2 and the maternally expressed H19 is
controlled by differential methylation at imprinting control
region 1 (ICR1),11,12 which contains binding sites for the zinc-
finger CCCTC-binding factor (CTCF) protein. DNA methyla-
tion at ICR1 on the paternal allele prevents CTCF binding and
is permissive for IGF2 gene expression. In contrast, CTCF can
bind the unmethylated maternal ICR1 and act as an insulator,
blocking the access of IGF2 promoters to the H19 downstream
enhancers, resulting in the activation of H19 expression. Loss of
imprinting at the IGF2/ICR1/H19 domain has been reported
in some cases of Beckwith-Wiedemann syndrome (BWS), which
is associated with prenatal overgrowth, and with Silver-Russell
syndrome (SRS), which is associated with profound pre- and
post-natal growth failure.13 Approximately 50% of growth-
restricted individuals with SRS cases show loss of methylation
at ICR1, which could lead to decreased IGF2 expression and
consequent growth restriction.8,14 IGF2 expression is addition-
ally modulated by DNA methylation at a number of other
DMRs, 15 and altered placental and umbilical cord 5mC at
DMRs controlling IGF2 expression has been reported in associ-
ation with fetal growth restriction in some,16-19 but not all15,20
studies.
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The maternally expressed cyclin dependent kinase 1C
(CDKN1C or p57KIP2) gene, located on the centromeric domain
of the chromosome 11p15 imprinting cluster, encodes a cyclin
dependent kinase inhibitor that induces cell cycle arrest and is a
major regulator of fetal growth.21,22 CDKN1C is expressed at
high levels in the placenta and its expression is regulated by DNA
methylation at a CpG island (KvDMR), which is normally meth-
ylated on the maternal allele.23 In mice, cdkn1c knockout or loss
of function mutations resulting in enhanced cell differentiation
and proliferation have been used to model BWS.22,24 While
mutations at CDKN1C occur in a small proportion of individuals
with BWS,25 in the majority of cases, there is loss of methylation
at KvDMR14,26,27 with associated silencing of CDKN1C. The
converse findings have been reported in SRS.28
5-hydroxymethylcytosine (5hmC) is a recently described cyto-
sine modification that may be an intermediate in the DNA
demethylation pathway 29 and is present in the placenta.30 Since
commonly used methods of assessing DNA methylation using
bisulfite conversion do not discriminate between 5mC and
5hmC, 31 previous studies reporting altered DNA methylation at
placental DMRs in association with fetal growth may be con-
founded. We used specific enrichment techniques to map 5mC
and 5hmC at the DMRs controlling the expression of IGF2 and
CDKN1C in human placenta, and additionally explored rela-
tionships between 5mC, 5hmC, gene expression, and fetal
growth across the full range of normal birth weight.
Methods
Cohort
Placental samples were collected from 72 women with a sin-
gleton pregnancy at term (>37 weeks) under the Edinburgh
Reproductive Tissue Bio-bank (ERTBB). Participants provided
full informed, written consent. The ERTBB works with ethical
and governance approval from the Scottish Academic Health Sci-
ences Collaboration (SAHSC), Human Annotated BioResource
(East of Scotland Research Ethics Service 13/ES/0126) and, pre-
viously, the West of Scotland Research Ethics Committee 4 (09/
S0704/3). Samples were collected at delivery by trained staff
from the center of the placenta (fetal side), away from the umbili-
cal cord and large vessels. Samples were snap-frozen or placed in
RNAlater with storage at ¡80C. Pregnancies complicated by
congenital abnormalities or diabetes were excluded. The sample
comprised babies with the full range of birth weight [mean
3467 g (SD 829 g)], including small for gestational age [SGA,
n D 21, birth weight <10th percentile, birth weight SD score
mean ¡1.85 (SD 0.44)], appropriate for gestational age [AGA,
n D 24, birth weight 10th¡90th percentiles, birth weight SD
score mean ¡0.36 (SD 0.79)], and large for gestational age
(LGA, n D 27, birth weight >90th percentile, birth weight SD
score mean 1.97 (SD 0.35)].
Gene expression
Total RNA was extracted from placenta using the Qiagen
RNeasy Fibrous Tissue Minikit (QIAGEN, Crawley, UK)
following the manufacturer’s instructions. High quality RNA
was obtained from 64 samples and the characteristics of these
64 did not differ from the whole dataset. RNA (1 mg) was
reverse transcribed using the Promega Reverse Transcription sys-
tem (Promega, Southampton, UK) and the expression of the
imprinted genes IGF2, H19 and CDKN1C was quantified using
real-time PCR using pre-designed assays (IGF2 and CDKN1C)
(Applied Biosystems, Warrington, UK), the Roche UPL System
(YWHAZ) or SYBR green technology (H19) (Roche, Burgess
Hill, UK) using a Roche LightCycler 480. YWHAZ was
chosen from a panel as the most stable reference gene using
Normfinder32 and geNormPLUS as part of the qbasePLUS soft-
ware (Eclipse v 3.7, Biogazelle, Zwijnaarde, Belgium). See
Table 1 for primer sequences.
Analysis of 5mC/5hmC
DNA was extracted from all 72 samples using DNeasy Blood
& Tissue Kit (Qiagen, Crawley, UK) with RNAse treatment
(Sigma-Aldrich, Dorset, UK). DNA was sonicated (200–300 bp
fragments for 5mC; 500-600 bp for 5hmC enrichment) using
the Covaris E220 Ultrasonicator (Covaris, MA, USA). 5mC
enrichment was performed using the Active Motif MethylCollec-
tor Ultra kit (Active Motif, La Hulpe, Belgium) as per the man-
ufacturer’s instructions. 5hmC enrichment was performed using
hydroxymethyl-DNA immunoprecipitation, as previously
described.33 Immunoprecipitated (ip) and input DNA were puri-
fied using the QIAquick PCR Purification Kit (Qiagen, Crawley,
Table 1. Primer sequences for real-time PCR. Primers for GAPDH and the
H19 gene body taken from.30 Coordinates refer to UCSC genome browser
hg18
Gene expression
Gene Assay details
Cyclin-dependent kinase inhibitor 1C
(CDKN1C)
Applied Biosystems: Hs00178938_m1
Insulin like growth factor 2 (IGF2) Applied Biosystems: Hs00171254_m1
H19 F:AACCCACAACATGAAAGAAATGG
R: AGAGGGTTTTGTGTCCGGATT
Tyrosine 3-monooxygenase/
tryptophan 5-mono-oxygenase
activation protein,
zeta polypeptide (YWHAZ)
F:GATCCCCAATGCTTCACAAG
R:TGCTTGTTGTGACTGATCGAC
UPL Probe no. 30
5mC/5hmC enrichment Assay details
GAPDH 30 F:CGGCTACTAGCGGTTTTACG
chr12:6513796-6513984 R:AAGAAGATGCGGCTGACTGT
H19 gene body 3 30 F: CTGGTGCTCACCTTCCAGAG
chr11:1973671-1973802 R: ATGGTGCTACCCAGCTCAAG
H19 gene body 4 30 F: GCCAGCTACACCTCCGTTG
chr11:1975242-1975378 R: AGCTAGGGCTGGAAAGAAGG
H19 gene body 1 30 F: CTCAGCTCTGGGATGATGTG
chr11:1973443C1973573 R: AGCCCAACATCAAAGACACC
H19 ICR (CTCF 6) F: AGTTGTGGAATCGGAAGTGG
chr11:1977617-1977807 R: GATAATGCCCGACCTGAAGA
IGF2 DMR0 F: TTTCATATTCCGTGCCATGA
chr11:2125774-2125987 R: CCTGCCTAGAGCTCCCTCTT
IGF2 DMR2 F: CGTTGAGGAGTGCTGTTTCC
chr11:2111194-2111431 R: CACAGCAAGCAAGGAAGTCA
KvDMR F: TGCGGATTCCAGACTCCAAT
chr11:2676925C2677065 R: GCTCCCATCTGCACCTTATG
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UK). Percentage enrichment of 5mC and 5hmC (ip/input) was
analyzed at the region of ICR1 containing the sixth CTCF bind-
ing site which is most consistently associated with the transcrip-
tional status of both IGF2 and H19;34 at 2 other DMRs known
to influence expression of IGF2 expression (DMR0, DMR2);
and at KvDMR, using real-time PCR with SYBR Green Tech-
nology. 5hmC enrichment within the H19 gene body was also
analyzed since previous studies have identified the region as
enriched for 5hmC. 30 As the ICR1 is known to be enriched for
5mC, the H19 gene body is enriched for 5hmC and the GAPDH
promoter is depleted for both modifications;30 enrichment at
these regions acted as positive and negative controls for each cyto-
sine modification. Primer details are given in Table 1.
Statistics
Weight measurements were adjusted for sex by converting to
SD scores (z-scores) and centiles using LMSgrowth version 2.71
(Pan H, Cole TJ. LMSgrowth, a Microsoft Excel add-in to access
growth references based on the LMS method. Version 2.71.
http://www.healthforallchildren.co.uk/; 2011). The data source
was “British 1990 reference data, reanalyzed 2009.” Values for
relative gene expression and percentage enrichment were natural
log transformed to achieve a normal distribution. Multivariate
linear regression analysis was used to test the hypothesis that birth
weight is associated with altered mRNA levels and 5mC or
5hmC enrichment. Covariates that could confound the associa-
tion or be in the causal pathway were added into the model and
included maternal body mass index (BMI), parity, smoking, and
pre-eclampsia. The outcome variable was birth weight standard
deviation (SD) score. Statistical significance was set at P < 0.05
(2-sided). Data were analyzed using SPSS version 19 (IBM, New
York, USA).
Results
Cohort
Characteristics of the mothers and babies are shown in
Table 2. For illustration, the data is presented as grouped by
SGA, AGA and LGA and includes variables used in the regres-
sion models. There were differences between groups in birth
weight, birth weight centiles and maternal BMI.
Gene expression
There was a positive correlation between birth weight SD
score and placental IGF2 mRNA levels (r D 0.30, P D 0.017),
which remained significant when adjusted for maternal BMI,
parity and pre-eclampsia (standardised b D 0.27, PD0.038)
(Fig. 1A). However, the association was lost when maternal
smoking was added into the model (standardized b D 0.20,
P D 0.104) or when offspring of mothers who smoked were
removed from the model (standardized b D 0.23, P D 0.085).
There was a negative correlation between birth weight SD
score and placental CDKN1C mRNA expression (r D ¡0.31,
P D 0.013) (Fig. 1B) which remained significant after adjust-
ment for maternal BMI, parity, pre-eclampsia and smoking
(standardized b D ¡0.26, P D 0.037) or when women who
smoked were removed from the analysis (standardized b D
¡0.27, P D 0.043).
Table 2. Characteristics of mothers and babies
SGA (nD21) AGA (nD24) LGA (nD27) P values
Birth weight, g, mean (SD) 2515 (201) 3250 (383) 4401 (189) <0.001
Birth weight centile, mean (SD) 4.38 (3.1) 38.3 (26.4) 96.9 (2.4) <0.001
Maternal BMI, kg/m2, mean (SD) 28.7 (8.2) 23.2 (2.9) 29.9 (6.1) <0.001
Pre-eclampsia, n (%) 4 (19.1) 0 0
Hypertension during pregnancy, n (%) 1 (4.8) 0 1 (3.7)
Smoking during pregnancy, n (%) 4 (19.1) 1 (4.2) 0
Primiparity, n (%) 7 (33.3) 8 (33.3) 3 (11.1)
Figure 1. Relationships between gene expression and birth weight. (A)
Relative expression of IGF2 vs. birth weight SD score and (B) relative
expression of CDKN1C vs. birth weight SD score.
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Analysis of 5mC and 5hmC
5mC enrichment was seen at DMR2, ICR1, and KvDMR
with lower levels of enrichment at DMR0 (Table 3). 5mC
enrichment at DMR0 and KvDMR was independently associ-
ated with birth weight SD score in adjusted analyses (Figs. 2A
and B) (DMR0: r D 0.37, P D 0.002 standardized b D 0.27, P
D 0.023; KvDMR: r D 0.29, P D 0.021 standardized b D 0.29,
P D 0.016). 5hmC enrichment was identified at all DMRs, nota-
bly DMR2 (Table 3). 5hmC enrichment within the H19 gene
body correlated with birth weight SD score in adjusted analyses
(Fig. 2C) (r D 0.27, P D 0.023; standardized b D 0.22, P D
0.041). There were no significant relationships between gene
mRNA levels and 5mC or 5hmC at any of the regions studied.
Discussion
Our results are in agreement with those from a number of pre-
vious studies showing the association of poor fetal growth with
decreased placental IGF2 expression.9 Here, we extend these
studies to show that this relationship holds across the range of
normal birth weight. Previous studies have reported decreased
IGF2 expression in placenta from SGA pregnancies,9,16 which
may occur from early on in pregnancy,35 and studies in mice con-
firm that IGF2 controls a substantial part of fetal growth.36
These data are consistent with the predicted effects of IGF2, since
paternally expressed genes augment fetal and placental develop-
ment. Although the number of women who smoked was small,
our data suggest that maternal smoking may explain part of this
relationship, since controlling for maternal smoking, or removing
smokers from the analysis weakened the association. An effect of
maternal smoking on IGF2 expression in placenta would not be
surprising since we have recently shown that maternal smoking
reduces IGF2 expression in human fetal liver.37 Maternally
expressed genes including CDKN1C act to restrict fetal and pla-
cental growth,38 and our data showing decreasing CDKN1C
expression with increased birth weight are consistent with this
and with a previous study reporting increased expression in asso-
ciation with SGA.10 Maternal smoking had no effect on
CDKN1C expression, suggesting that any effects of smoke expo-
sure are gene-specific, again consistent with our previous data in
human fetal liver.37
5mC enrichment at IGF2 DMR0 and KvDMR was positively
related to birth weight SD score. However the consequences of
this are unclear, since there was no correlation between
DNA methylation at these regions and IGF2 and CDKN1C
mRNA levels. The lack of correlation between mRNA levels and
DNA methylation is consistent with previous studies in umbilical
cord and placenta which report altered
expression of a number of imprinted
genes in the absence of the correspond-
ing expected changes in DNA methyla-
tion20,39 and suggests that alternative
mechanisms may lead to dysregulation
of the expression of these genes in the
placenta. 5hmC enrichment within the
H19 gene body was also positively
related to birth weight SD score.
Although 5hmC is about 10-fold less
abundant than 5mC across the
genome, this varies across tissues and
genomic location.40 In addition to its
role in DNA demethylation, 5hmC is
a stable and functional epigenetic mark
41 and is enriched in the bodies of
actively transcribed genes, at a number
of transcription start sites, and at
CTCF binding sites.30,42,43 We identi-
fied significant enrichment of 5hmC at
DMR2 and, although 5hmC is also
known to be present at some imprinted
DMRs, including across IGF2-H19, its
precise role at these loci is unclear.30
However, studies that show that H19
remains highly enriched for 5hmC in
Table 3. Percentage enrichment of 5mC and 5hmC at individual DMRs.
Locus 5mC % enrichment
(ip/input). Mean § SE
5hmC % enrichment
(ip/input). Mean § SE
GAPDH 0 0.12 § 0.02
DMR0 3.79 § 0.64 3.27 § 0.37
DMR2 28.73§ 2.15 21.38 § 2.07
ICR1 42.91§ 2.24 3.12 § 0.39
KvDMR 57.16§ 4.85 1.53 § 0.13
H19 gene body Not tested 4.87 § 0.34
Figure 2. Relationships between 5mC, 5hmC, and birth weight. (A) Percentage enrichment of 5mC at
IGF2 DMR0 versus birth weight SD score, (B) percentage enrichment of 5mC at KvDMR vs. birth weight
SD score and (C) percentage enrichment of 5hmC at H19 gene body vs. birth weight SD score.
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cell culture despite the global loss of 5hmC elsewhere,43 and that
such loci are also protected from demethylation in the post-fertil-
ization embryo,44 suggest that 5hmC dynamics at imprinted loci
may differ from those in the remainder of the genome. Addition-
ally, since 5hmC may be an intermediate in the DNA demethyla-
tion pathway, 5hmC at DMRs could result from the conversion
of 5mC during the demethylation process.29
Both 5mC and 5hmC are resistant to deamination by bisulfite
conversion, so that the cytosine methylation quantified using bisul-
fite conversion represents the sum of 5mC and 5hmC levels.31
Although the techniques used in our study do not permit us to com-
pare the relative enrichment of 5mC and 5hmC quantitatively, the
presence of 5hmC within DMRs in imprinted regions in human
placenta mean that studies of DNAmethylation using conventional
bisulfite conversion might overestimate 5mC levels at DMRs, par-
ticularly if the results of such studies are used to infer potential
effects of altered methylation on gene expression. Our findings of
significant enrichment of 5hmC and a lower enrichment of 5mC at
DMR2 relative to the other DMRs analyzed suggest that studies
using bisulfite conversion techniques that report small changes in
cytosine methylation at DMRs, including at this region,18 could
overestimate the amount of 5mC present. Additionally, the pres-
ence of (and/or changes in) 5hmC at the same loci could complicate
any interpretation of downstream effects on gene expression, since
the role of 5hmC at imprinted DMRs is unclear.
The strengths of this study are the use of methods specific for
the detection of 5mC and 5hmC and the inclusion of babies
with birth weights across the normal range. Limitations of our
study include that we were unable to quantify the relative
amounts of 5mC and 5hmC at each locus; however, now that we
have identified the presence of these marks at imprinted DMRs
in placenta, future studies utilizing techniques such as Tet-
assisted bisulfite (TAB) sequencing or oxidative bisulfite sequenc-
ing will allow more specific quantitation of 5mC/5hmC at indi-
vidual CpGs. Such studies would permit genome-wide analysis,
rather than the more limited approach of studying 5mC and
5hmC at specific DMRs known to have an impact on birth
weight. We used placental DNA in our analysis, and studies that
utilize available tissue from the offspring (cord blood, umbilical
cord, buccal cells) would provide additional information as to
mechanisms accounting for offspring disease risk.45 Our study
included relatively low numbers of women who smoked and this
means that although we were able to identify smoking as a con-
founder for IGF2 expression, we were not powered to undertake
formal testing of mediation. We did not have access to placental
weights for this study, which would have been useful for further
analysis of any relationship between placenta weight, gene expres-
sion, and DNA methylation. Finally, further work to relate
changes in DNA methylation, gene, and protein expression
would also be useful in determining the underlying mechanisms
of disease.
In conclusion, we show that for 2 imprinted loci, placental
gene expression and 5mC/5hmC patterns associate with size at
birth. We also show that 5hmC is present at some imprinted loci
and suggest that studies aimed at describing DNA methylation in
placenta should consider using specific techniques that distin-
guish between different DNA modifications and permit their
accurate quantification. This would facilitate our further under-
stand of the mechanisms that underpin fetal and placental
growth, which, by extension, might be important in determining
later disease risk.
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